Merck
HomeWebinarsVirtual Symposium: How mRNA Technology Impacts our Future

Virtual Symposium: How mRNA Technology Impacts our Future



WEBINAR

The pandemic and the unprecedented success of mRNA-based COVID-19 vaccines have drawn attention and interest to mRNA technology, making it one of the most attractive technologies today.

In this technical symposium, industry experts present various aspects of mRNA technology and the latest trends in the field.

During this symposium, you will:

  • Learn about the potential of mRNA technology
  • Get perspectives on a robust mRNA manufacturing process and efficient drug delivery

Speakers

Tanja Henzler, Ph.D.

Tanja Henzler, Ph.D.

Merck

Director, Liquid Formulation R&D

Tanja Henzler studied biology in Tübingen and received her Ph.D. in virology at the Ruprechts Karls University Heidelberg. She joined Merck in 2002 with a focus on protein characterization and protein analytics. After evaluating new technologies for the life science business of the company, she coordinated an interdisciplinary and cross-divisional innovation project. She now leads the liquid formulation R&D department, focusing on protein stability and controlled release of biomolecules.

Nargisse El Hajjami, Ph.D. Eng.

Nargisse El Hajjami, Ph.D. Eng.

Merck

Senior Consultant

Nargisse El Hajjami, Ph.D. Eng. is a senior consultant for novel modalities and the global lead for mRNA technology within our bioprocessing strategy operationalization group. Nargisse is a molecular microbiologist and bioprocess expert with 11 years of experience combining scientific research, process development, and biomanufacturing engineering. In her current role, Nargisse focuses on novel modalities business development by leading strategic initiatives, supporting go-to-market strategies, providing directions to operationalize the business strategy, as well as supporting customers to build, grow, and optimize their manufacturing processes.

Ulrich Reichert, Ph.D.

Ulrich Reichert, Ph.D.

Merck

Global Regulatory Management

Ulrich Reichert heads the regulatory management - pharma and food materials organization of the life science business of Merck KGaA, Darmstadt, Germany. He is responsible for registration of APIs and excipients with health authorities (master files), and he acts as the principal contact for site registration with the GMP-supervisory authority. Ulrich is a pharmacist by training, holds a Ph.D. and an M.S. in drug regulatory affairs, and has more than 20 years of experience in quality and regulatory requirements for raw and starting materials in the pharmaceutical industry.

Olivia Merkel, Ph.D.

Olivia Merkel, Ph.D.

LMU Munich, Department of Pharmacy

Drug Delivery Professor

Olivia Merkel is a professor of drug delivery in the department of pharmacy at LMU Munich. She was an assistant professor of pharmaceutics and an associate faculty member of oncology at Wayne State University, Detroit, heading research labs both in Detroit and Munich. Her research centers around targeted RNA delivery in cancer, inflammatory diseases, and viral infections with a focus on pulmonary administration. Prof. Merkel holds a Ph.D. in pharmaceutical technology from Philipps-Universität Marburg and received several awards. She is an author of more than 100 articles and book chapters and a member of several scientific organizations.

Christopher J. Barbosa, Ph.D.

Christopher J. Barbosa, Ph.D.

Acuitas Therapeutics

Senior Director, Technology Development

Christopher J. Barbosa joined Acuitas Therapeutics in 2014 and has been part of the company’s rise to a leadership position in the application of lipid nanoparticle (LNP) technology for the delivery of nucleic acid therapeutics. He collaborates with Acuitas partners on a wide range of lipid nanoparticle therapeutic applications such as mRNA encoded antibody therapies, gene editing, and vaccines, including the first approved COVID-19 vaccine – the mRNA-LNP therapeutic COMIRNATY® – produced in collaboration with a BioNTech/Pfizer partnership. The Acuitas proprietary delivery technology is a key part of the innovation leading to this highly effective vaccine. He holds a Ph.D. in chemistry and biotechnology from The University of British Columbia, Canada, and has held several leadership roles in the research and development of novel drug delivery systems.